Navigation Links
Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Medical Mutual

MINNEAPOLIS, Dec. 23, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that Medical Mutual has written a positive coverage policy for Percutaneous Tibial Nerve Stimulation (PTNS) delivered via Uroplasty's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.  Medical Mutual is a large, regional private insurer with approximately 2.7 million covered lives, primarily in Ohio, as well as Georgia, Indiana, Michigan, Pennsylvania, South Carolina and West Virginia.

"This new policy reflects our continuing efforts to educate payers on the clinical benefits and cost effectiveness of Urgent PC therapy," said Nancy Kolb, Vice President of Healthcare Policy and Reimbursement.  "With the addition of Medical Mutual, we now have approximately 108 million lives covered by private payers and 40 million Medicare beneficiaries with access to Urgent PC therapy."

The policy is available on the Medical Mutual site at

About Overactive Bladder

Overactive bladder (OAB) is a chronic condition that affects approximately 34 million US adults.  The symptoms include urinary urgency, frequency and urge incontinence.  The Urgent PC Neuromodulation System is the only FDA cleared device that delivers Percutaneous Tibial Nerve Stimulation (PTNS) therapy. 

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical company committed to offering transformative treatment options to specialty physicians.  Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at

Forward-Looking Information
This press release contains forward-looking statements that reflect our best estimates regarding future events and financial performance.  These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our anticipated results.  We discuss in detail the factors that may affect the achievement of our forward-looking statements in our Annual Report on Form 10-K filed with the SEC.

For Further Information:

Uroplasty, Inc.

Rob Kill

President and CEO


EVC Group

Leigh Salvo (Investors)


Janine McCargo (Media)


SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Uroplasty Names David B. Perry Vice President Of Marketing
2. Uroplasty Provides Update On PTNS Reimbursement
3. Uroplasty To Participate In The Piper Jaffray Healthcare Conference
4. Uroplasty Announces Positive Coverage Decision For Percutaneous Tibial Nerve Stimulation By Humana, Inc.
5. Uroplasty Sets New Quarterly Revenue Record During Fiscal Second Quarter 2014
6. Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
7. Class Action Lawsuit Against Uroplasty Dismissed
8. Uroplasty Appoints Brett Reynolds As Chief Financial Officer
9. Uroplasty Reports Fiscal First Quarter 2014 Financial Results
10. Uroplasty Completes Internal Control Review; Files Form 10-K for Fiscal 2013
11. Uroplasty Announces Delay in Filing Form 10-K
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... , ... PRMA Plastic Surgery is updating their record books yet again with ... flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, says ... it’s an honor to have served all of these women.” , PRMA is one ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... than those found on mammography, according to a study published online in the ... not seen on mammography may necessitate a change in treatment. , Breast MRI ...
(Date:11/25/2015)... ... November 25, 2015 , ... TyloHelo Inc ... and accessories. , Sauna accessories help improve the bather experience in the sauna, ... basic styles for the purist looking for simplicity in design to accessories that ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... According to ... surgical robot is being more and more widely heralded as a breakthrough for performing ... Vinci method has over traditional laparoscopic surgery is that it can greatly reduce the ...
(Date:11/25/2015)... ... 2015 , ... The McHenry County law firm of Botto Gilbert Lancaster, ... Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant ... (2d) 130884WC. , According to court documents, Adcock testified that on May 10, 2010 ...
Breaking Medicine News(10 mins):